OrbusNeich Medical

What OrbusNeich Medical does

OrbusNeich Medical Group Holdings Limited is a Hong Kong-listed (HKEx:6929) multinational medical device company founded in 2000 by Teddy Chien, specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Its portfolio spans an extensive range of high-performance balloons (Sapphire 3, Sapphire II PRO, ScoreFlex scoring balloons, JADE non-compliant PTA balloons across 014/018/035/Rx variants), the COMBO Plus dual therapy coronary stent, and the Teleport microcatheter — built around proprietary technologies such as P-TECH shafts, Sub-zero Tip Technology, Hydro-X hydrophilic coatings, and a nitinol integral scoring wire. The company is extending into structural heart via the TricValve Transcatheter Bicaval Valves system (marketed through the P&F joint venture formed in 2020) for tricuspid regurgitation in high-risk or inoperable patients. Manufacturing is vertically integrated across three sites: Shenzhen (R&D and production, established 2001), Hoevelaken in the Netherlands (EMEA HQ and production, acquired 2005), and Weil am Rhein in Germany (acquired with eucatech AG in 2023), with a fourth Hangzhou facility under construction toward 2027 operations.

OrbusNeich monetizes through direct hardware sales of single-use interventional devices to hospitals, cardiac centers, and vascular centers, with FY2025 revenue of US$180.5 million (+10.0% YoY) on 2.02 million units sold (+16.2% YoY), generating US$122.4M gross profit (~67.8% gross margin) and US$41.9M net income attributable to owners. Pricing is not publicly disclosed. Distribution is a hybrid model combining direct enterprise sales forces in 15+ countries (Belgium, France, Germany, Hong Kong, Indonesia, Japan, Luxembourg, Macau, Malaysia, Monaco, Netherlands, Singapore, Spain, Switzerland, Taiwan) with an independent distributor network covering more than 70 countries across six continents — and the company has been actively converting distributors into direct sales via acquisitions in Switzerland (2020), Indonesia (PT Revass, 84% stake for ~US$15M in November 2023), South Korea (SJ Medicare, 2023), and Taiwan (2025). Key customer segments are interventional cardiologists and vascular specialists performing coronary and peripheral procedures, with secondary exposure to structural heart programs; go-to-market is supported by participation in major cardiovascular congresses (EuroPCR, TCTAP, CCT), the OrbusNeich Academy training platform, and the "Simplify the Complex" clinical education initiative. The company is led by Chairman/CEO David Chien, with COO Denise Lau and CFO Jason Chen, and operates with a founder-family-influenced governance structure following its 2022 HKEx listing that raised approximately HK$481 million.

Name

OrbusNeich Medical

Legal name

OrbusNeich Medical Group Holdings Limited

Website

https://orbusneich.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

OrbusNeich Medical is a Hong Kong-listed multinational medical device company that designs, manufactures, and sells interventional balloons, stents, microcatheters, and transcatheter valves for PCI, PTA, and structural heart procedures, distributed through direct sales in 15+ countries and a 70-country distributor network.

Ownership category

akta.pro rank

Product category

Interventional Cardiology & Vascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)

akta.pro secondary industries

Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE), Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK), Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

Keywords

• Interventional cardiology devices
• Coronary stent systems
• Balloon catheter products
• Peripheral vascular devices
• Structural heart valves

Headquarters

HQ city

Sha Tin

HQ country

Hong Kong SAR China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Medical Device Sales: OrbusNeich generates revenue through the sale of interventional cardiology and peripheral vascular devices including balloons, stents, and specialty catheters. FY2025 results showed revenue of US$180.5 million with sales volume of 2.02 million units.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

OrbusNeich Medical designs, develops, manufactures, and markets interventional medical devices for the treatment of vascular diseases. Its core product lines include the COMBO Plus dual therapy coronary stent, the Sapphire family of balloon catheters, ScoreFlex scoring balloons, JADE PTA balloons, the Teleport microcatheter, and the TricValve transcatheter bicaval valve system. These devices are used by interventional cardiologists and vascular specialists in hospitals and cardiac centers for percutaneous coronary intervention (PCI), percutaneous transluminal angioplasty (PTA), and structural heart procedures.

Product overview

OrbusNeich Medical is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. The company's core product portfolio includes an extensive range of high-performance balloons (Sapphire, ScoreFlex, JADE families), coronary stents (COMBO Plus dual therapy stent), and specialty catheters (Teleport microcatheter). The company is actively expanding into structural heart disease through the TricValve transcatheter bicaval valves system. OrbusNeich sells products to over 70 countries and regions worldwide, with direct sales operations across Europe, Asia-Pacific, and the Middle East, supported by manufacturing facilities in Shenzhen (China), Hoevelaken (Netherlands), and Weil am Rhein (Germany).

Differentiator

Problem solved

Functional benefit

Brands

• P&F (Products & Features): Structural heart therapy division focusing on TricValve Transcatheter Bicaval Valves for treatment of tricuspid regurgitation

Products and services

• COMBO Plus Dual Therapy Stent Coronary dual therapy stent combining high radial strength with excellent side branch access; provides both mechanical support and therapeutic drug delivery for restenosis prevention. Used by interventional cardiologists in PCI procedures for the treatment of coronary artery disease.
• Sapphire 3 Coronary Balloon Catheter Latest generation coronary dilatation catheter in the Sapphire family, designed for tackling complex lesions with advance solutions, available in 0.85mm–1.0mm diameters. Used in PCI procedures.
• Sapphire NC24 High-Pressure Non-Compliant Balloon Catheter High-pressure non-compliant balloon catheter with high pressure tolerance for preparing tight, calcified lesions and stent optimization in PCI procedures.
• Sapphire II PRO Balloon Catheter (1.0mm–4.0mm) Balloon dilatation catheter with P-TECH shaft for optimal pushability and kink resistance, featuring Sub-zero Tip Technology for smooth lesion entry; semi-compliant for crossing difficult lesions and tracking tortuous anatomy; first generation Sapphire received CE Mark in April 2007.
• ScoreFlex NC Scoring Balloon Catheter Coronary scoring balloon for plaque modifications in fibrotic and moderately calcified lesions during PCI procedures, providing focused force dilatation.
• ScoreFlex PTA Scoring Balloon Catheter Focused force dilatation balloon with dual-wire system creating focal stress pattern for safe and controlled plaque modification at lower resolution pressure in PTA procedures. Features nitinol integral wire scoring element; available in AV Fistula, SFA, and BTK configurations.
• JADE PTA Balloon Catheter Family Non-compliant PTA balloon catheter family with hybrid OTW/RX design offering the highest rated burst pressure amongst competitor products of the same class. Hydro-X hydrophilic coating enhances crossability. Includes JADE 035, JADE 018, JADE 014, and JADE Rx variants for peripheral vessel preparation and optimization in PTA procedures.
• Teleport Microcatheter Microcatheter designed for ultimate torquability, trackability, and safety to maximize guidewire support and luminal access in complex coronary and peripheral lesions. Features tungsten radiopaque tip and hybrid braiding and coil construction for great distal flexibility.
• TricValve Transcatheter Bicaval Valves System System of two self-expanding biological valves for percutaneous treatment of patients with hemodynamically relevant tricuspid insufficiency and caval reflux. Valves are implanted percutaneously into the superior and inferior vena cava. Sold under the P&F (Products & Features) structural heart sub-brand.

Quantifiable outcome

• FY2025 revenue of US$180.5 million, up 10.0% year-on-year
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core.

• Taiwan DistributorcoreChannel Partner/ Reseller/ Distributor · 1 January 2025Acquired distributor in Taiwan to enhance direct sales network in Taiwan, continuing the company's strategy of acquiring distributors to expand direct sales presence.
• PT Revass Utama MedikacoreChannel Partner/ Reseller/ Distributor · 27 November 2023OrbusNeich acquired an 84% stake in PT Revass, an Indonesian distributor, for approximately US$15 million. The acquisition enhances OrbusNeich's direct sales capabilities in Indonesia's growing medical industry where PT Revass has a significant sales network.
• SJ MedicarecoreChannel Partner/ Reseller/ Distributor · 27 November 2023OrbusNeich acquired SJ Medicare, a South Korean distributor, to strengthen the sales network in Korea as part of the company's expansion of direct sales operations.
• eucatech AGcoreStrategic or Co-development Partner · 1 January 2023OrbusNeich acquired eucatech AG, a German medical engineering company, to enrich product offerings and expand manufacturing capabilities in Germany (Weil am Rhein facility).
• Products & Features International, LDAcoreStrategic or Co-development Partner · 1 October 2020Strategic joint venture formed for the development, manufacturing, and distribution of structural heart products in certain countries in Asia Pacific regions. This partnership supports OrbusNeich's expansion into structural heart disease treatments including the TricValve product line.
• Swiss DistributorcoreChannel Partner/ Reseller/ Distributor · 1 August 2020Acquired distributor in Switzerland to actively expand direct sales network in the European market.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Boston Scientific: One of the world's largest interventional cardiology and peripheral vascular device companies, with broad overlapping franchises in drug-eluting stents, balloons, and structural heart. A scale incumbent whose commercial reach and R&D budget dwarf OrbusNeich's, but serves the same hospital cardiology customers.
• Medtronic: Global medtech leader with a major coronary and structural heart portfolio (including TAVR). Directly competes with OrbusNeich's PCI stent and balloon businesses and dominates the structural heart categories that TricValve targets.
• Abbott Laboratories: Operates one of the largest vascular and structural heart device franchises worldwide (XIENCE stents, MitraClip, TriClip). OrbusNeich's CCO Alain KHAIR was previously at Abbott, reflecting the close competition for interventional cardiology accounts.

Direct peers

• Terumo: Japan-headquartered interventional systems company with overlapping coronary stent, balloon catheter, and access device portfolios. Particularly comparable in Asia-Pacific markets where OrbusNeich is most established.
• Biotronik: German privately-held manufacturer of coronary stents, balloon catheters, and vascular intervention devices. Highly comparable mid-sized European competitor with overlapping product categories and similar OEM/distributor-led go-to-market model.
• B. Braun: German medical device and pharmaceutical group with a significant interventional vascular portfolio (including coronary and peripheral balloon catheters). Comparable manufacturing presence in Germany (OrbusNeich has a Weil am Rhein facility via eucatech AG).
• MicroPort Scientific: Hong Kong-listed Chinese medtech company with a large cardiovascular intervention franchise (stents, balloons, structural heart). Closest geographic and product peer to OrbusNeich, competing in Asia-Pacific, EMEA, and emerging markets.
• Teleflex: US-listed interventional and surgical device company with vascular access and specialty catheter products overlapping OrbusNeich's microcatheter and access device families. Comparable mid-cap scale and hospital-focused sales motion.

Emerging players

• Penumbra: US-listed company focused on vascular thrombectomy and peripheral intervention. Overlaps with OrbusNeich's peripheral vascular portfolio and shares a similar growth profile in hospital-based interventional procedures.

Others

• Cardiovascular Systems (Abbott): Acquired by Abbott in 2023, previously a leading orbital atherectomy company that OrbusNeich distributed for worldwide beginning in 2018. Provides ecosystem context for OrbusNeich's peripheral vascular offering and competitive set.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/OrbusNeich

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries9 records

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OrbusNeich Medical